BNP Paribas Financial Markets Purchases 18,534 Shares of Savara Inc (NASDAQ:SVRA)

BNP Paribas Financial Markets raised its position in shares of Savara Inc (NASDAQ:SVRA) by 258.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,693 shares of the company’s stock after purchasing an additional 18,534 shares during the quarter. BNP Paribas Financial Markets’ holdings in Savara were worth $109,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of SVRA. Bank of New York Mellon Corp lifted its stake in shares of Savara by 12.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock valued at $1,162,000 after buying an additional 32,142 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Savara by 967.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company’s stock valued at $177,000 after acquiring an additional 39,886 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after acquiring an additional 6,973 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Savara during the second quarter worth about $527,000. Finally, Choreo LLC purchased a new stake in shares of Savara during the second quarter worth about $59,000. 87.93% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Joseph S. Mccracken purchased 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the acquisition, the director now owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.13% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, HC Wainwright dropped their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.17.

Savara Stock Performance

NASDAQ:SVRA opened at $3.02 on Thursday. The company has a market cap of $518.29 million, a price-to-earnings ratio of -7.02 and a beta of 0.92. Savara Inc has a 1 year low of $2.82 and a 1 year high of $5.70. The stock’s 50 day simple moving average is $3.49 and its two-hundred day simple moving average is $4.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, equities analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.